Cargando…
SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality
Background: In Turner Syndrome (TS) it is recommended to induce puberty around 11-12 years of age, by initiating hormone replacement therapy (HRT), when premature ovarian failure is diagnosed. However, evidence for the long-term effects on morbidity and mortality is sparse and it is unknown how many...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552127/ http://dx.doi.org/10.1210/js.2019-SAT-284 |
_version_ | 1783424530329370624 |
---|---|
author | Viuff, Mette Berglund, Agnethe Juul, Svend Andersen, Niels Stochholm, Kirstine Gravholt, Claus |
author_facet | Viuff, Mette Berglund, Agnethe Juul, Svend Andersen, Niels Stochholm, Kirstine Gravholt, Claus |
author_sort | Viuff, Mette |
collection | PubMed |
description | Background: In Turner Syndrome (TS) it is recommended to induce puberty around 11-12 years of age, by initiating hormone replacement therapy (HRT), when premature ovarian failure is diagnosed. However, evidence for the long-term effects on morbidity and mortality is sparse and it is unknown how many TS receive HRT as recommended according to guidelines. Aim: To describe the incidence of cardiovascular and endocrine related morbidity and mortality, and the association with HRT in TS. Design: Nationwide epidemiological study using Danish registries on medications and healthcare contacts. Methods: We identified 1.156 women with Turner Syndrome diagnosed from 1960-2014 using The Danish Cytogenetic Central Registry and linked them with the Danish National Patient Register and the Medication Statistics Register. Statistics Denmark randomly identified 115.578 controls matched on gender and age. We used Stratified Cox regression to analyze morbidity, mortality and prescriptions, computing proportional hazard ratios (HR). Results: Women with TS had more than doubled risk of cardiovascular diseases such as arrhythmia, heart failure, hypertension, ischemic heart disease, stroke, and endocrine diseases such as thyroid disorders. Similar a 4-fold increase in the risk of diabetes type I and II and osteoporosis was seen. Many TS (17-33% depending on karyotype) never received HRT. Overall mortality in TS was 3-fold increased. Among TS with 45,X receiving HRT, mortality was lower than among HRT non-treated 45,X (HR 5.0 (3.0-8.2) vs. HR 3.0 (1.9-4.5)). We saw a significant reduction in use of antihypertensive medication (HR 0.5 (95% CI 0.4-0.7)), antidiabetics (HR 0.4 (95% CI 0.2-0.9)) and thyroid hormones (HR 0.5 (95% CI 0.3-0.9)) in HRT treated 45,X women compared to HRT non-treated 45,X women. Conclusion: 17-33% of TS women never received HRT. Mortality is increased 3-fold in all TS compared with controls, and 45,X women that did receive HRT had a lover mortality than those who did not. HRT have a beneficial effect on endocrine conditions, hypertension and stroke. |
format | Online Article Text |
id | pubmed-6552127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65521272019-06-13 SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality Viuff, Mette Berglund, Agnethe Juul, Svend Andersen, Niels Stochholm, Kirstine Gravholt, Claus J Endocr Soc Pediatric Endocrinology Background: In Turner Syndrome (TS) it is recommended to induce puberty around 11-12 years of age, by initiating hormone replacement therapy (HRT), when premature ovarian failure is diagnosed. However, evidence for the long-term effects on morbidity and mortality is sparse and it is unknown how many TS receive HRT as recommended according to guidelines. Aim: To describe the incidence of cardiovascular and endocrine related morbidity and mortality, and the association with HRT in TS. Design: Nationwide epidemiological study using Danish registries on medications and healthcare contacts. Methods: We identified 1.156 women with Turner Syndrome diagnosed from 1960-2014 using The Danish Cytogenetic Central Registry and linked them with the Danish National Patient Register and the Medication Statistics Register. Statistics Denmark randomly identified 115.578 controls matched on gender and age. We used Stratified Cox regression to analyze morbidity, mortality and prescriptions, computing proportional hazard ratios (HR). Results: Women with TS had more than doubled risk of cardiovascular diseases such as arrhythmia, heart failure, hypertension, ischemic heart disease, stroke, and endocrine diseases such as thyroid disorders. Similar a 4-fold increase in the risk of diabetes type I and II and osteoporosis was seen. Many TS (17-33% depending on karyotype) never received HRT. Overall mortality in TS was 3-fold increased. Among TS with 45,X receiving HRT, mortality was lower than among HRT non-treated 45,X (HR 5.0 (3.0-8.2) vs. HR 3.0 (1.9-4.5)). We saw a significant reduction in use of antihypertensive medication (HR 0.5 (95% CI 0.4-0.7)), antidiabetics (HR 0.4 (95% CI 0.2-0.9)) and thyroid hormones (HR 0.5 (95% CI 0.3-0.9)) in HRT treated 45,X women compared to HRT non-treated 45,X women. Conclusion: 17-33% of TS women never received HRT. Mortality is increased 3-fold in all TS compared with controls, and 45,X women that did receive HRT had a lover mortality than those who did not. HRT have a beneficial effect on endocrine conditions, hypertension and stroke. Endocrine Society 2019-04-30 /pmc/articles/PMC6552127/ http://dx.doi.org/10.1210/js.2019-SAT-284 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Pediatric Endocrinology Viuff, Mette Berglund, Agnethe Juul, Svend Andersen, Niels Stochholm, Kirstine Gravholt, Claus SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title | SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title_full | SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title_fullStr | SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title_full_unstemmed | SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title_short | SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality |
title_sort | sat-284 sex hormone replacement therapy in turner syndrome and the impact on morbidity and mortality |
topic | Pediatric Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552127/ http://dx.doi.org/10.1210/js.2019-SAT-284 |
work_keys_str_mv | AT viuffmette sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality AT berglundagnethe sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality AT juulsvend sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality AT andersenniels sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality AT stochholmkirstine sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality AT gravholtclaus sat284sexhormonereplacementtherapyinturnersyndromeandtheimpactonmorbidityandmortality |